The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion for Truberzi ( Eluxadoline ) in the European Union.

Truberzi is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults.
In two pivotal trials, Truberzi has significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and diarrhoea, with sustained relief demonstrated over six months.
Truberzi was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain.

Eluxadoline has a novel dual mechanism of action and acts on both agonist-antagonist opioid receptors in the gastrointestinal tract.

IBS is common worldwide, with an estimated global prevalence of around 11%. Around one third of IBS patients are estimated to have IBS-D.
In a pan-European survey, it is estimated that approximately 3.5 million people ( 1.4% of the population ) across western European countries have IBS-D ( France, Germany, Italy, Spain, and the UK ).
IBS-D can severely affect patient quality of life and in some cases it can be very debilitating. ( Xagena )

Source: Allergan, 2016